{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:34:01Z","timestamp":1791473641688,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-15-1-0265"],"award-info":[{"award-number":["W81XWH-15-1-0265"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-16-1-0557"],"award-info":[{"award-number":["W81XWH-16-1-0557"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"U.S. Department of Health &amp; Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["U54HD090245"],"award-info":[{"award-number":["U54HD090245"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"U.S. Department of Health &amp; Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["U54HD090245"],"award-info":[{"award-number":["U54HD090245"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"U.S. Department of Health &amp; Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["U54HD090245"],"award-info":[{"award-number":["U54HD090245"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["MDA353094"],"award-info":[{"award-number":["MDA353094"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0557"],"award-info":[{"award-number":["W81XWH-16-1-0557"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0557"],"award-info":[{"award-number":["W81XWH-16-1-0557"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0557"],"award-info":[{"award-number":["W81XWH-16-1-0557"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Extensive biomarker discoveries for DMD have occurred in the past 7 years, and a vast array of these biomarkers were confirmed in independent cohorts and across different laboratories. In these previous studies, glucocorticoids and age were two major confounding variables. In this new study, using SomaScan technology and focusing on a subset of young DMD patients who were not yet treated with glucocorticoids, we identified 108 elevated and 70 decreased proteins in DMD relative to age matched healthy controls (p value\u2009&lt;\u20090.05 after adjusting for multiple testing). The majority of the elevated proteins were muscle centric followed by cell adhesion, extracellular matrix proteins and a few pro-inflammatory proteins. The majority of decreased proteins were of cell adhesion, however, some had to do with cell differentiation and growth factors. Subsequent treatment of this group of DMD patients with glucocorticoids affected two major groups of pharmacodynamic biomarkers. The first group consisted of 80 serum proteins that were not associated with DMD and either decreased or increased following treatment with glucocorticoids, and therefore were reflective of a broader effect of glucocorticoids. The second group consisted of 17 serum proteins that were associated with DMD and these tended to normalize under treatment, thus reflecting physiologic effects of glucocorticoid treatment in DMD. In summary, we have identified a variety of circulating protein biomarkers that reflect the complex nature of DMD pathogenesis and response to glucocorticoids.<\/jats:p>","DOI":"10.1038\/s41598-019-48548-9","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T10:02:54Z","timestamp":1566381774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy"],"prefix":"10.1038","volume":"9","author":[{"given":"Yetrib","family":"Hathout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ogundele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganggang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shefa M.","family":"Tawalbeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh J","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gordish-Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie S.","family":"Conklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean K.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Henricson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"issue":"7","key":"48548_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.15252\/emmm.201303724","volume":"6","author":"B Ayoglu","year":"2014","unstructured":"Ayoglu, B. et al. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Molecular Medicine 6(7), 918\u2013936 (2014).","journal-title":"EMBO Molecular Medicine"},{"key":"48548_CR2","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1073\/pnas.1507719112","volume":"112","author":"Y Hathout","year":"2015","unstructured":"Hathout, Y. et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences 112, 7153\u20137158 (2015).","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"48548_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/jcsm.12304","volume":"9","author":"P Spitali","year":"2018","unstructured":"Spitali, P. et al. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. Journal of Cachexia, Sarcopenia and Muscle 9(4), 715\u2013726 (2018).","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"issue":"5","key":"48548_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/emmm.201100133","volume":"3","author":"D Cacchiarelli","year":"2011","unstructured":"Cacchiarelli, D. et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Molecular Medicine 3(5), 258\u2013265 (2011).","journal-title":"EMBO Molecular Medicine"},{"key":"48548_CR5","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1038\/mtna.2014.29","volume":"3","author":"X Li","year":"2014","unstructured":"Li, X. et al. Circulating Muscle-specific miRNAs in Duchenne Muscular Dystrophy Patients. Molecular Therapy - Nucleic Acids 3, e177 (2014).","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"11","key":"48548_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.molmed.2017.09.002","volume":"23","author":"A Coenen-Stass","year":"2017","unstructured":"Coenen-Stass, A., Wood, M. & Roberts, T. Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy. Trends in Molecular Medicine 23(11), 989\u20131001 (2017).","journal-title":"Trends in Molecular Medicine"},{"key":"48548_CR7","doi-asserted-by":"publisher","first-page":"e0153461","DOI":"10.1371\/journal.pone.0153461","volume":"11","author":"S Boca","year":"2016","unstructured":"Boca, S. et al. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLOS ONE 11, e0153461 (2016).","journal-title":"PLOS ONE"},{"key":"48548_CR8","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1111\/jcmm.13543","volume":"22","author":"P Spitali","year":"2018","unstructured":"Spitali, P. et al. Cross-sectional serum metabolomic study of multiple forms of muscular dystrophy. Journal of Cellular and Molecular Medicine 22, 2442\u20132448 (2018).","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"48548_CR9","doi-asserted-by":"crossref","unstructured":"Coenen-Stass, A. et al. Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Scientific Reports 5 (2015).","DOI":"10.1038\/srep17014"},{"key":"48548_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3892\/ijmm.2017.2952","volume":"39","author":"S Murphy","year":"2017","unstructured":"Murphy, S. et al. Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy. International Journal of Molecular Medicine 39, 1357\u20131370 (2017).","journal-title":"International Journal of Molecular Medicine"},{"key":"48548_CR11","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1021\/pr2001385","volume":"10","author":"L Guevel","year":"2011","unstructured":"Guevel, L. et al. Quantitative Proteomic Analysis of Dystrophic Dog Muscle. Journal of Proteome Research 10, 2465\u20132478 (2011).","journal-title":"Journal of Proteome Research"},{"key":"48548_CR12","doi-asserted-by":"publisher","first-page":"e0194485","DOI":"10.1371\/journal.pone.0194485","volume":"13","author":"C Brinkmeyer-Langford","year":"2018","unstructured":"Brinkmeyer-Langford, C. et al. Expression profiling of disease progression in canine model of Duchenne muscular dystrophy. Plos One 13, e0194485 (2018).","journal-title":"PLOS ONE"},{"key":"48548_CR13","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1093\/hmg\/ddv214","volume":"24","author":"J Rouillon","year":"2015","unstructured":"Rouillon, J. et al. Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. Human Molecular Genetics 24, 4916\u20134932 (2015).","journal-title":"Human Molecular Genetics"},{"key":"48548_CR14","doi-asserted-by":"crossref","unstructured":"Hathout, Y. et al. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Scientific Reports 6 (2016).","DOI":"10.1038\/srep31727"},{"key":"48548_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cyto.2017.12.006","volume":"102","author":"S de Carvalho","year":"2018","unstructured":"de Carvalho, S., Matsumura, C., Santo Neto, H. & Marques, M. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy. Cytokine 102, 55\u201361 (2018).","journal-title":"Cytokine"},{"key":"48548_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DNND.S121099","volume":"8","author":"C Al-Khalili Szigyarto","year":"2018","unstructured":"Al-Khalili Szigyarto, C. & Spitali, P. Biomarkers of Duchenne muscular dystrophy: current findings. Degenerative Neurological and Neuromuscular Disease 8, 1\u201313 (2018).","journal-title":"Degenerative Neurological and Neuromuscular Disease"},{"key":"48548_CR17","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1093\/hmg\/ddu366","volume":"23","author":"Y Hathout","year":"2014","unstructured":"Hathout, Y. et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Human Molecular Genetics 23, 6458\u20136469 (2014).","journal-title":"Human Molecular Genetics"},{"key":"48548_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","volume":"136","author":"L Conklin","year":"2018","unstructured":"Conklin, L. et al. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research 136, 140\u2013150 (2018).","journal-title":"Pharmacological Research"},{"key":"48548_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1074\/jbc.273.1.157","volume":"273","author":"B Gilpin","year":"1998","unstructured":"Gilpin, B. et al. A Novel, Secreted Form of Human ADAM 12 (Meltrin \u03b1) Provokes Myogenesis in vivo. Journal of Biological Chemistry 273, 157\u2013166 (1998).","journal-title":"Journal of Biological Chemistry"},{"key":"48548_CR20","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1242\/jcs.02397","volume":"118","author":"R Krauss","year":"2005","unstructured":"Krauss, R. et al. Close encounters: regulation of vertebrate skeletal myogenesis by cell-cell contact. Journal of Cell Science 118, 2355\u20132362 (2005).","journal-title":"Journal of Cell Science"},{"key":"48548_CR21","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1091\/mbc.e09-12-1011","volume":"21","author":"G Bae","year":"2010","unstructured":"Bae, G. et al. Cdo Interacts with APPL1 and Activates AKT in Myoblast Differentiation. Molecular Biology of the Cell 21, 2399\u20132411 (2010).","journal-title":"Molecular Biology of the Cell"},{"key":"48548_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/emboj\/21.1.114","volume":"21","author":"J Kang","year":"2002","unstructured":"Kang, J., Mulieri, P., Hu, Y., Taliana, L. & Krauss, R. BOC, an Ig superfamily member, associates with CDO to positively regulate myogenic differentiation. The EMBO Journal 21, 114\u2013124 (2002).","journal-title":"The EMBO Journal"},{"key":"48548_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0092-8674(94)90192-9","volume":"79","author":"S Arber","year":"1994","unstructured":"Arber, S., Halder, G. & Caroni, P. Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell 79, 221\u2013231 (1994).","journal-title":"Cell"},{"key":"48548_CR24","doi-asserted-by":"publisher","first-page":"11154","DOI":"10.3390\/molecules200611154","volume":"20","author":"M Anaya-Segura","year":"2015","unstructured":"Anaya-Segura, M. et al. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection. Molecules 20, 11154\u201311172 (2015).","journal-title":"Molecules"},{"key":"48548_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0960-8966(94)90066-3","volume":"4","author":"O Hardiman","year":"1994","unstructured":"Hardiman, O. Dystrophin deficiency, altered cell signaling and fibre hypertrophy. Neuromuscular Disorders 4, 305\u2013315 (1994).","journal-title":"Neuromuscular Disorders"},{"key":"48548_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0303-8467(95)00013-A","volume":"97","author":"S Pradhan","year":"1995","unstructured":"Pradhan, S. & Mittal, B. Infraspinatus muscle hypertrophy and wasting of axillary folds as the important signs in Duchenne muscular dystrophy. Clinical Neurology and Neurosurgery 97, 134\u2013138 (1995).","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"48548_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/jnnp.35.4.451","volume":"35","author":"WG Bradley","year":"1972","unstructured":"Bradley, W. G., Hudgson, P., Larson, P. F., Papapetropoulos, T. A. & Jenkison, M. Structural changes in the early stages of Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry 35, 451\u2013455 (1972).","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"48548_CR28","doi-asserted-by":"crossref","unstructured":"Duddy, W. et al. Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia. Skeletal Muscle 5 (2015).","DOI":"10.1186\/s13395-015-0041-y"},{"key":"48548_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/apha.12114","volume":"208","author":"K Hollinger","year":"2013","unstructured":"Hollinger, K. & Selsby, J. The physiological response of protease inhibition in dystrophic muscle. Acta Physiologica 208, 234\u2013244 (2013).","journal-title":"Acta Physiologica"},{"key":"48548_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1357-2725(99)00095-3","volume":"32","author":"J Tidball","year":"2000","unstructured":"Tidball, J. & Spencer, M. Calpains and muscular dystrophies. The International Journal of Biochemistry & Cell Biology 32, 1\u20135 (2000).","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"48548_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.nmd.2014.03.012","volume":"24","author":"J Rouillon","year":"2014","unstructured":"Rouillon, J. et al. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. Neuromuscular Disorders 24, 563\u2013573 (2014).","journal-title":"Neuromuscular Disorders"},{"key":"48548_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.nmd.2017.05.009","volume":"27","author":"A Robertson","year":"2017","unstructured":"Robertson, A. et al. Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents. Neuromuscular Disorders 27, 635\u2013645 (2017).","journal-title":"Neuromuscular Disorders"},{"key":"48548_CR33","doi-asserted-by":"crossref","unstructured":"Childers, M. et al. Chronic Administration of a Leupeptin-Derived Calpain Inhibitor Fails to Ameliorate Severe Muscle Pathology in a Canine Model of Duchenne Muscular Dystrophy. Frontiers in Pharmacology 2 (2012).","DOI":"10.3389\/fphar.2011.00089"},{"key":"48548_CR34","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00018-005-5533-1","volume":"63","author":"A Bosch-Comas","year":"2006","unstructured":"Bosch-Comas, A., Lindsten, K., Gonz\u00e0lez-Duarte, R., Masucci, M. & Marfany, G. The ubiquitin-specific protease USP25 interacts with three sarcomeric proteins. Cellular and Molecular Life Sciences 63, 723\u2013734 (2006).","journal-title":"Cellular and Molecular Life Sciences"},{"key":"48548_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.afnr.2017.12.003","volume":"84","author":"J Hoffman","year":"2018","unstructured":"Hoffman, J., Varanoske, A. & Stout, J. Effects of \u03b2-Alanine Supplementation on Carnosine Elevation and Physiological Performance. Advances in Food and Nutrition Research 84, 183\u2013206 (2018).","journal-title":"Advances in Food and Nutrition Research"},{"key":"48548_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/ageing\/29.3.207","volume":"29","author":"S Gariballa","year":"2000","unstructured":"Gariballa, S. & Sinclair, A. Review. Carnosine: physiological properties and therapeutic potential. Age and Ageing 29, 207\u2013210 (2000).","journal-title":"Age and Ageing"},{"key":"48548_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/metabo7030038","volume":"7","author":"M Abdullah","year":"2017","unstructured":"Abdullah, M. et al. Non-Targeted Metabolomics Analysis of Golden Retriever Muscular Dystrophy-Affected Muscles Reveals Alterations in Arginine and Proline Metabolism, and Elevations in Glutamic and Oleic Acid In Vivo. Metabolites 7, 38 (2017).","journal-title":"Metabolites"},{"key":"48548_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00292-017-0265-1","volume":"38","author":"K Ohlendieck","year":"2017","unstructured":"Ohlendieck, K. & Swandulla, D. Molekulare Pathogenese der Fibrose bei Muskeldystrophie vom Typ Duchenne. Der Pathologe 38, 21\u201329 (2017).","journal-title":"Der Pathologe"},{"key":"48548_CR39","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/art.24936","volume":"60","author":"H Bilgic","year":"2009","unstructured":"Bilgic, H. et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis & Rheumatism 60, 3436\u20133446 (2009).","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"48548_CR40","first-page":"3069","volume":"8","author":"X Yin","year":"2015","unstructured":"Yin, X. et al. CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy. International Journal of Clinical and Experimental Pathology 8(3), 3069\u201375 (2015).","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"48548_CR41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/prca.201500044","volume":"10","author":"S Oonk","year":"2016","unstructured":"Oonk, S. et al. Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients. PROTEOMICS - Clinical Applications 10, 290\u2013299 (2016).","journal-title":"PROTEOMICS - Clinical Applications"},{"key":"48548_CR42","doi-asserted-by":"crossref","unstructured":"Abou-Samra, M. et al. Involvement of adiponectin in the pathogenesis of dystrophinopathy. Skeletal Muscle 5 (2015).","DOI":"10.1186\/s13395-015-0051-9"},{"key":"48548_CR43","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.ajpath.2017.02.018","volume":"187","author":"M Abou-Samra","year":"2017","unstructured":"Abou-Samra, M., Boursereau, R., Lecompte, S., Noel, L. & Brichard, S. Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy. The American Journal of Pathology 187, 1577\u20131585 (2017).","journal-title":"The American Journal of Pathology"},{"key":"48548_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1513\/pats.200402-001MS","volume":"1","author":"I Adcock","year":"2004","unstructured":"Adcock, I., Ito, K. & Barnes, J. Glucocorticoids: Effects on Gene Transcription. Proceedings of the American Thoracic Society 1, 247\u2013254 (2004).","journal-title":"Proceedings of the American Thoracic Society"},{"key":"48548_CR45","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"C McDonald","year":"2018","unstructured":"McDonald, C. et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391, 451\u2013461 (2018).","journal-title":"Lancet"},{"key":"48548_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"C McDonald","year":"2013","unstructured":"McDonald, C. et al. The cooperative international neuromuscular research group duchenne natural history study-a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used. Muscle & Nerve 48, 32\u201354 (2013).","journal-title":"Muscle & Nerve"},{"key":"48548_CR47","doi-asserted-by":"publisher","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","volume":"5","author":"L Gold","year":"2010","unstructured":"Gold, L. et al. Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLoS ONE 5, e15004 (2010).","journal-title":"PLoS ONE"},{"key":"48548_CR48","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/pmic.201300187","volume":"14","author":"B Lollo","year":"2014","unstructured":"Lollo, B., Steele, F. & Gold, L. Beyond antibodies: New affinity reagents to unlock the proteome. Proteomics 14, 638\u2013644 (2014).","journal-title":"PROTEOMICS"},{"key":"48548_CR49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series 57, 289\u2013300 (1995).","journal-title":"Journal of the Royal Statistical Society Series"},{"key":"48548_CR50","unstructured":"Core Team, R. R: A language and environment for statistical computing. R Foundation for Statistical Computing. R-project.org at, https:\/\/www.R-project.org\/ (2018)."},{"key":"48548_CR51","doi-asserted-by":"crossref","unstructured":"Kuznetsova, A., Brockhoff, P. & Christensen, R. lmerTest Package: Tests in Linear Mixed Effects Models. Journal of Statistical Software 82 (2017).","DOI":"10.18637\/jss.v082.i13"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48548-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48548-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48548-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T09:54:11Z","timestamp":1721642051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48548-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48548"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48548-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"20 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12167"}}